Second-line treatment for renal cell cancer.
作者信息
Di Lorenzo G, De Placido S, Buonerba C
出版信息
Br J Cancer. 2012 Feb 14;106(4):617-8. doi: 10.1038/bjc.2011.611.
Abstract
摘要
相似文献
1
Second-line treatment for renal cell cancer.
Br J Cancer. 2012 Feb 14;106(4):617-8. doi: 10.1038/bjc.2011.611.
2
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur J Cancer. 2016 Sep;65:102-8. doi: 10.1016/j.ejca.2016.06.016. Epub 2016 Jul 31.
3
Intermittent sunitinib for metastatic renal cell carcinoma.
Lancet Oncol. 2017 Mar;18(3):e139. doi: 10.1016/S1470-2045(17)30082-7. Epub 2017 Feb 3.
4
Benefits of pazopanib over sunitinib for renal cell carcinoma.
Lancet Oncol. 2016 Mar;17(3):e93. doi: 10.1016/S1470-2045(16)00081-4. Epub 2016 Feb 5.
5
Mixed Results for Sunitinib in Renal Cancer.
Cancer Discov. 2017 Jan;7(1):OF6. doi: 10.1158/2159-8290.CD-NB2016-142. Epub 2016 Nov 9.
6
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Adv Ther. 2017 Nov;34(11):2452-2465. doi: 10.1007/s12325-017-0628-2. Epub 2017 Oct 26.
7
Hypertension as a predictive factor of Sunitinib activity.
Ann Oncol. 2007 Jun;18(6):1117. doi: 10.1093/annonc/mdm184.
8
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795.
9
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795.
10
Pazopanib versus sunitinib in renal cancer.
N Engl J Med. 2013 Nov 14;369(20):1968-9. doi: 10.1056/NEJMc1311795.
引用本文的文献
1
Metastasis of renal cell carcinoma to the buccal mucosa 19 years after radical nephrectomy.
Case Rep Oncol Med. 2012;2012:823042. doi: 10.1155/2012/823042. Epub 2012 Oct 22.
本文引用的文献
1
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
Br J Cancer. 2012 Apr 24;106(9):1475-80. doi: 10.1038/bjc.2012.89. Epub 2012 Mar 22.
2
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4.
3
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Br J Cancer. 2011 Nov 22;105(11):1635-9. doi: 10.1038/bjc.2011.389. Epub 2011 Oct 27.
4
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21.
5
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Clin Drug Investig. 2011;31(7):507-17. doi: 10.2165/11590230-000000000-00000.
6
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.
Br J Cancer. 2011 Feb 1;104(3):399-406. doi: 10.1038/sj.bjc.6606084.
7
Toxicities of targeted therapy and their management in kidney cancer.
Eur Urol. 2011 Apr;59(4):526-40. doi: 10.1016/j.eururo.2011.01.002. Epub 2011 Jan 14.
8
Sunitinib and other targeted therapies for renal cell carcinoma.
Br J Cancer. 2011 Mar 1;104(5):741-5. doi: 10.1038/sj.bjc.6606061. Epub 2011 Jan 25.
9
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
BJU Int. 2011 Sep;108(5):665-72. doi: 10.1111/j.1464-410X.2010.09957.x. Epub 2011 Jan 25.
10
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24.
Zotero 插件